Drug skin tests and systemic cutaneous adverse drug reactions: An update

Expert Review of Dermatology

Volumn 2, Issue 4, 2007, Pages 481-495

  Barbaud, Annick ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

lactam antibiotics; Antibiotics; Corticosteroids; Cutaneous adverse drug reaction; Drug skin tests; Intradermal tests; Patch tests; Prick tests; Radiocontrast media

Indexed keywords

ACICLOVIR; AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CAPTOPRIL; CARBAMAZEPINE; CEFCAPENE PIVOXIL; CELECOXIB; CHLOROQUINE; CHLORPHENIRAMINE; CLINDAMYCIN; CLOBAZAM; CODEINE; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYAMEMAZINE; DESLORATADINE; DIAZEPAM; DICLOFENAC; DILTIAZEM; ENOXAPARIN; ESTROGEN; FAMCICLOVIR; FLUINDIONE; FUSAFUNGINE; GANCICLOVIR; GENTAMICIN; ISONIAZID; QUINOLONE DERIVATIVE; UNINDEXED DRUG;

ANGIONEUROTIC EDEMA; CROSS REACTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SENSITIZATION; ECZEMA; EOSINOPHILIA; FALSE POSITIVE RESULT; FLUSHING; HUMAN; INTRACUTANEOUS TEST; MACULOPAPULAR RASH; PATCH TEST; PHOTOSENSITIVITY; PRICK TEST; PRIORITY JOURNAL; PUSTULOSIS; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN DISEASE; SKIN TEST; STANDARDIZATION; STEVENS JOHNSON SYNDROME; SYSTEMIC DISEASE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

EID: 34547899908     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.4.481     Document Type: Review

References (118)

1. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 209, 209-216 (2005).
2. Barbaud A, Reichert-Penetrat S, Trechot P et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br. J. Dermatol. 139, 49-58 (1998).
3. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 45, 321-328 (2001).
4. Barbaud A, Bene MC, Faure G, Schmutz JL. Tests cutanés dans l'exploration des toxidermies supposées de mécanisme immuno-allergique. Bull. Acad. Natl. Med. 184, 47-63 (2000).
5. Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J. Dermatol. 17, 235-239 (1990).
6. Bruynzeel DP, Van Ketel WG. Patch testing in drug eruptions. Semin. Dermatol. 8, 196-203 (1989).
7. Barbaud A. Tests cutanés dans l'investigation des toxidermies: de la physiopathologie aux résultats des investigations. Therapie 57, 258-262 (2002).
8. Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br. J. Dermatol. 116, 561-567 (1987).
9. Bruynzeel DP, Van Ketel WG. Skin tests in the diagnosis of maculopapular drug eruptions. Semin. Dermatol. 6, 119-124 (1987).
10. Romano A, Di Fonso M, Pietrantonio F et al. Repeated patch testing in delayed hypersensitivity to β-lactam antibiotics. Contact Dermatitis 28, 190 (1993).
11. Barbaud A, Bene MC, Schmutz JL, Ehlinger A, Weber M, Faure GC. Role of delayed cellular hypersensitivity and adhesion molecules in maculopapular rashes induced by amoxicillin. Arch. Dermatol. 133, 481-486 (1997).
12. Fernandez T, Torres MJ, R-Pena R et al. Decrease of selective immunoglobulin E response to amoxicillin despite repeated administration of benzylpenicillin and penicillin V. Clin. Exp. Allergy 35, 1645-1650 (2005).
13. Britschgi M, Steiner UC, Schmid S et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J. Clin. Invest. 107, 1433-1441 (2001).
14. Felix RH, Comaish JS. The value of the patch tests and other skin tests in drug eruptions. Lancet 1, 1017-1019 (1974).
15. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 57, 45-51 (2002).
16. Wolkenstein P, Chosidow O, Flechet M-L et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35, 234-236 (1996).
17. Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke WH. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 47, 100-102 (2002).
18. Barbaud A, Bursztejn AC, Vernassiere C, Schmutz JL. Trechot Ph. Toxidermie à l'Aerius®: les patch-tests avec la desloratadine induisent des faux positifs. Ann. Dermatol. Vénéréol. 132, s71 (2005).
19. Barbaud A, Trechot P, Reichert-Penetrat S, Commun N, Schmutz JL. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis 45, 265-268 (2001).
20. Conilleau V, Dompmartin A, Michel M, Verneuil L, Leroy D. Photoscratch testing in systemic drug-induced photosensitivity. Photodermatol. Photoimmunol. Photomed. 16, 62-66 (2000).
21. Lammintausta K, Mäkela L, Kalimo K. Rapid systemic valaciclovir reaction subsequent to aciclovir contact. Allergy Contact Dermatitis 45, 181 (2001).
22. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis 41, 185-189 (1999).
23. Klein CE, Trautmann A, Zillikens D, Brocker EB. Patch testing in an unusual case of toxic epidermal necrolysis. Contact Dermatitis 33, 448-449 (1995).
24. Barbaud A, Trechot P, Reichert-Penetrat S, Granel F, Schmutz JL. Drug patch testing: the usefulness in testing on the most previously affected site in a systemic cutaneous adverse drug reaction to tetrazepam. Contact Dermatitis 44, 259-260 (2001).
25. Wilkinson DS, Fregert S, Magnusson B et al. Terminology of contact dermatitis. Acta Dermatovenereol. (Stockholm) 50, 287-292 (1970).
26. Jonker MJ, Bruynzeel D. Anaphylactic reaction elicited by patch testing with diclofenac. Contact Dermatitis 49, 114-115 (2003).
27. Romano A, Guéant-Rodriguez RM, Viola M et al. Diagnosing immediate reactions to cephalosporins. Clin. Exp. Allergy 35(9), 1234-1242 (2005).
28. Co Minh HB, Bousquet PJ, Fontaine C, Kvedariene V, Demoly P. Systemic reactions during skin tests with Β-lactams: a risk factor analysis. J. Allergy Clin. Immunol. 117, 466-448 (2006).
29. Laxenaire MC, Moneret-Vautrin DA. Anaphylactic reactions to rocuronium. Br. J. Anaesth. 85, 325-326 (2000).
30. Torres M-J, Sanchez-Sabate E, Alvarez J et al. Skin test evaluation in nonimmediate allergic reactions to penicillins. Allergy 59, 219-224 (2004).
31. Rodriguez-Bada JL, Montanez MI, Torres MJ et al. Skin testing for immediate hypersensitivity to betalactams: comparison between two commercial kits. Allergy 61, 947-951 (2006).
32. Antunez C, Blanca-Lopez N, Torres MJ et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J. Allergy Clin. Immunol. 117, 404-410 (2006).
33. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br. J. Dermatol. 152, 968-974 (2005).
34. Romano A, Viola M, Mondino C et al. Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int. Arch. Allergy Immunol. 129, 169-174 (2002).
35. Bernedo N, Gonzalez I, Gastaminza G, Audicana M, Fernandez E, Munoz D. Positive patch test in vancomycin allergy. Contact Dermatitis 45, 43 (2001).
36. Hausermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 51, 297-310 (2004).
37. Romano A, Di Fonso M, Papa G et al. Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy 50, 113-118 (1995).
38. Barbaud A, Trechot P, Weber-Muller F, Ulrich G, Commun N, Schmutz JL. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis 50, 22-26 (2004).
39. Menczer J, Barda G, Glezerman M et al. Hypersensitivity reaction to carboplatin. Results of skin tests. Eur. J. Gynaecol. Oncol. 20, 214-216 (1999).
40. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J. Clin. Oncol. 21, 4611-4614 (2003).
41. Leguy-Seguin V, Jolimoy G, Coudert B et al. Diagnostic and predictive value of skin testing in platinum salts hypersensitivity. J. Allergy Clin. Immunol. 119, 726-730 (2007).
42. Brockow K, Becker EW, Worret WI, Ring J. Late skin test reactions to radiocontrast medium. J. Allergy Clin. Immunol. 104, 1107-1108 (1999).
43. Vernassiere C, Trechot P, Schmutz JL, Barbaud A. Results and negative value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis 50, 359-366 (2004).
44. Brockow K, Christiansen C, Kanny G et al.; ENDA; EAACI interest group on drug hypersensitivity. Management of hypersensitivity reactions to iodinated contrast media. Allergy 60, 150-158 (2005).
45. Gueant-Rodriguez RM, Romano A, Barbaud A, Brockow K, Gueant JL. Hypersensitivity reactions to iodinated contrast media. Curr. Pharm. Des. 12, 3359-3372 (2006).
46. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 61, 1432-1440 (2006).
47. Ludwig RJ, Beier C, Lindhoff-Last E, Kaufmann R, Boehncke WH. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 49, 158-159 (2003).
48. Romano A, Viola M, Mondino C et al. Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int. Arch. Allergy Immunol. 129, 169-174 (2002).
49. Kilpio K, Hannuksela M. Corticosteroid allergy in asthma. Allergy 58, 1131-1135 (2003).
50. Buettiker U, Keller M, Pichler WJ, Braathen LR, Yawalkar N. Oral prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group A confirmed by epicutaneous testing and lymphocyte transformation tests. Dermatology 213, 40-43 (2006).
51. Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis 48, 137-139 (2003).
52. Cholez C, Trechot P, Schmutz JL, Faure G, Bene MC, Barbaud A. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers. Allergy 58, 1207-1209 (2003).
53. Sanchez TS, Sanchez-Perez J, Aragues M, Garcia-Diaz A. Flare-up reaction of pseudoephedrine baboon syndrome after positive patch test. Contact Dermatitis 42, 312-313 (2000).
54. Pirker C, Misic A, Brinkmeier T, Frosch PJ. Tetrazepam drug sensitivity - usefulness of the patch test. Contact Dermatitis 47, 135-138 (2002).
55. Akiyama M, Nakada T, Sueki H, Fujisawa R, Iijima M. Drug eruption caused by non-ionic iodinated X-ray contrast media. J. Acad. Radiol. 5, s159-s161 (1998).
56. Vernassiere C, Barbaud A, Trechot PH, Weber-Muller F, Schmutz JL. Systemic acyclovir reaction subsequent to acyclovir contact allergy: which systemic antiviral drug should then be used? Contact Dermatitis 49, 155-157 (2003).
57. Sakakibara T, Hata M, Numano K et al. Fixed-drug eruption caused by allylisopropylacetylutea. Contact Dermatitis 44, 189-190 (2001).
58. Gaig P, San Miguel-Moncin MM, Bartra J, Bonet A, Garcia-Ortega P. Usefulness of patch tests for diagnosing selective allergy to captopril. J. Investig. Allergol. Clin. Immunol. 11, 204-206 (2001).
59. Kawada A, Aragane Y, Maeda A, Asai M, Shiraishi H, Tezuka T. Drug eruption induced by cefcapene pivoxilhydrochloride. Contact Dermatitis 44, 197 (2001).
60. Verbeiren S, Morant C, Charlanne H, Ajebbar K, Caron J, Modiano P. Toxidermie due au celecoxib aver tests épicutané positif. Ann. Dermatol. Venereol. 129, 203-205 (2002).
61. Machet L, Vaillant L, Dardaine V, Lorette G. Patch testing with clobazam: relapse of generalized drug eruption. Contact Dermatitis 26, 347-348 (1992).
62. Brown VL, Orton DI. Cutaneous adverse drug reaction to oral chlorphenamine detected with patch testing. Contact Dermatitis 52, 49-50 (2005).
63. Estrada JL, Alvarez Puebla MJ, Ortiz de Urbina JJ, Matilla B, Prieto MA, Gozalo F. Generalized eczema due to codeine. Contact Dermatitis 44, 185 (2001).
64. Frouin E, Roth B, Grange A, Grange F, Tortel MC, Guillaume JC. Syndrome d'hypersensibilité à la fluindione (Préviscan®). Positivité des tests épicutanés. Ann. Dermatol. Venereol. 132, 1000-1002 (2005).
65. Rodriguez-Morales A, Alonso Llamazares A, Palacios Benito R, Martinez Cocera C. Fixed drug eruption from quinolones with a positive lesional patch test to ciprofloxacin. Contact Dermatitis 44, 255 (2001).
66. Scherer K, Bircher AJ. Hypersensitivity reactions to fluoroquinolones. Curr. Allergy Asthma Rep. 5, 15-21 (2005).
67. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin. Exp. Allergy 36, 59-69 (2006).
68. Rebello S, Sanchez P, Vega JM et al. Hypersensitivity syndrome from isoniazid with positive patch test. Contact Dermatitis 45, 306 (2001).
69. Gonzalo-Garijo MA, de Arila D, Rodriguez-Nevado I. Generalized reaction after patch testing with metamizol. Contact Darmatitis 45, 180 (2001).
70. Quinones Estevez D, Fernandez Schmitz C. Exanthema to metamizole. Allegy 56,262-263 (2001).
71. Sasaki K, Yamamoto T, Kishi M, Yokozeki H, Nishiaka K. Acute exanthematous pustular drug eruption induced by mexiletine. Eur. J. Dermatol. 11, 469-471 (2001).
72. Anturies A, Davril A, Trechot P, Grandidier M, Truchetet F, Cuny JF. Syndrome d'hypersensibilité à la minocycline. Ann. Dermatol. Venereol. 126, 518-521 (1999).
73. Grange-Prunier A, Roth B, Kleinclaus I, Fagot JP, Guillaume JC. Pustulose exanthématique aigue generalisee due au carbimazole (Neomercazole): premier cas et valeur des patch tests. Ann. Dermatol. Venereol. 133; 709-710 (2006).
74. Malheiro D, Cadinha S, Rodrigues J, Vaz M, Castel-Branco MG. Nimesulide-induced fixed drug eruption. Allergol. Immunopathol. (Madr.) 33, 285-287 (2005).
75. Barranco R, Tornero P, De Barrio M, De Frutos C, Rodriguez A, Rubio M. Type IV hypersensitivity to oral nystatin. Contact Dermatitis 45, 60 (2001).
76. Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch. Dermatol. 139, 1181-1183 (2003).
77. Montoro J, Diaz M, Genis C, Lozano A, Bertomeu F. Non-pigmenting cutaneous-mucosal fixed drug eruption due to piroxicam. Allergol. Immunopathol. 31, 53-55 (2003).
78. Wong DA, Freeman S. Cutaneous allergic reaction to intramuscular vitamin K1. Australas. J. Dermatol. 40, 147-152 (1999).
79. Antunez C, Martin E, Cornejo-Garcia JA et al. Immediate hypersensitivity reactions to penicillins and other β-lactams. Curr. Pharm. Des. 12, 3327-3333 (2006).
80. Bonadonna P, Schiappoli M, Senna G, Passalacqua G. Delayed selectivr reaction to clavulanic acid: a case report. J. Investig. Allergol. Clin. Immunol. 15, 302-304 (2005).
81. Torres MJ, Romano A, Mayorga C et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: the role of skin testing. Allergy 56, 850-856 (2001).
82. AE1-Qutob D, Morales C, Pelaez A. Allergic reaction caused by articaine. Allergol. Immunopathol. (Madr.) 33, 115-116 (2005).
83. Berkun Y, Ben-Zvi A, Levy Y, Galili D, Shalit M. Evaluation of adverse reactions to local anesthetics: experience with 236 patients. Ann. Allergy Asthma Immunol. 91, 342-345 (2003).
84. Herrero T, Tornero P, Infante S et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J. Investig. Allergol. Clin. Immunol. 16, 327-330 (2006).
85. Notman MJ, Phillips EJ, Knowles SR, Weber EA, Shear NH. Clindamycin skin testing has limited diagnostic potential. Contact Dermatitis. 53, 335-338 (2005).
86. Padial A, Posadas S, Alvarez J et al. Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism. Allergy 60, 665-670 (2005).
87. Venturini M, Lobera T, del Pozo MD, González I, Blasco A. Immediate hypersensitivity to corticosteroids. J. Investig. Allergol. Clin. Immunol. 16, 51-56 (2006).
88. Caceres Calle O, Fernandez-Benitez M. Allergy to dexchlorpheniramine. Study of a case. Allergol. Immunopathol. (Madr.) 32, 306-309 (2004).
89. Beaudouin E, Kanny G, Blanloeil Y, Guilloux L, Renaudin JM, Moneret-Vautrin DA. Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Allerg. Immunol. (Paris) 35, 382-385 (2003).
90. Jappe U, Juschka U, Kuner N, Hausen BM, Krohn K. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 51, 67-72 (2004).
91. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb. Haemost. 94, 1265-1269 (2005).
92. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb. Haemost. 96, 611-617 (2006).
93. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alternative anticoaglant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb. Haemost. 97, 496-467 (2007).
94. Adachi A, Fukunaga A, Horikawa T. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-actin insulin. Int. J. Dermatol. 43, 597-599 (2004).
95. Lee AY, Chey WY, Choi J, Jeon JS. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm. Venereol. 82, 114-117 (2002).
96. Takahama H, Tsutsumi Y, Kubota Y. Anaphylaxis due to levofloxacin. Int. J. Dermatol. 44, 799-790 (2005).
97. Buergin S, Scherer K, Hausermann P, Bircher AJ. Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance. Int. Arch. Allergy Immunol. 140, 20-26 (2006).
98. Strauss RM, Green ST, Gawkrodger DJ. Rifampicin allergy confirmed by an intradermal test, but with a negative patch test. Contact Dermatitis 45, 108 (2001).
99. Patel VJ, Bruck MC, Katz BE. Hypersensitivity reaction to hyaluronic acid with negative skin testing. Plast. Reconstr. Surg. 117, 92e-94e (2006).
100. Fays S, Trechot P, Schmutz JL, Cuny JF, Truchetet F, Barbaud A. Bupropion and generalized acute urticaria: eight cases. Br. J. Dermatol. 148, 177-178 (2003).
101. Trujillo MJ, de Barrio M, Rodriguez A et al. Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report. Allergol. Immunopathol (Madr.) 29, 133-136 (2001).
102. Gonçalo M, Figueiredo A. Cross-reactions among oxicams in cutaneous adverse drug reactions. Contact Dermatitis 46, s31 (2002).
103. Barranco R, Rodriguez A, de Barrio M et al. Sympathomimetic drug allergy: cross-reactivity study by patch test. Am. J. Clin. Dermatol. 5, 351-355 (2004).
104. Romano A, Pettinato R, Andriolo M et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr. Pharm. Des. 12, 3373-3381 (2006).
105. Viola M, Quaratino D, Gaeta F et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int. Arch. Allergy Immunol. 137, 145-150 (2005).
106. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest 126, 400-404 (2004).
107. Van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch. Intern. Med. 158, 2063-2065 (1998).
108. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 72, 162-164 (2001).
109. Maalouf T, Angioi K, Champigneulle J, Guerci A, George JL. Oedeme palpebral secondaire a un traitement par un inhibiteur de tyrosine kinase (Glivec). A propos d'un cas. J. Fr. Ophtalmol. 27, 107-109 (2004).
110. Esmaeli B, Prieto VG, Butler CE et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95, 881-887 (2002).
111. Zink M, Kuwilsky A, Knopf U. Olanzapine-associated bilateral eyelid edcma. J. Clin. Psychopharmacol. 27, 214-215 (2007).
112. Chandeclerc ML, Martin S, Petitpain N, Barbaud A, Schmutz JL. Tadalafil and palpebral edema. South Med. J. 97, 1142-1143 (2004).
113. Romano A, Quaratino D, Papa G, Di Fonso M, Venuti A. Aminopenicillin allergy. Arch. Dis. Child. 76, 513-517 (1997).
114. Torres MJ, Mayorga C, Leyva L et al. Controlled administration of penicillin to patients with a positive history but negative skin and specific serum IgE tests. Clin. Exp. Allergy 32, 270-276 (2002).
115. Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann. Intern. Med. 140, 1001-1006 (2004).
116. Ponvert C, Weilenmann C, Wassenberg J et al. Allergy to betalactam antibiotics in children: a prospective follow-up study in retreated children after negative responses in skin and challenge tests. Allergy 62, 42-46 (2007).
117. Demoly P, Benahmed S, Sahla H et al. Allergy to macrolides. 21 cases. Presse Med. 29, 294-298 (2000).
118. Ulrich G, Schmutz JL, Trechot PH, Commun N, Barbaud A. Sensitization to petrolatum: an unusual cause of false positive drug patch tests. Allergy 59, 1006-1009 (2004).